基于希拉季特的纳米载体如何改变经典阿霉素向乳腺癌细胞（MCF-7和ZR-75-1）的递送。
How Shilajit-Based Nanocarriers Alter Classical Doxorubicin Delivery to Breast Cancer Cells (MCF-7 and ZR-75-1).
作者信息
Asadi Zahra, Jalilian Saba, Arkan Elham, Aghaz Faranak
机构信息
Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah 67158 47141, Iran.
Department of Clinical Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah 67158 47141, Iran.
出版信息
ACS Med Chem Lett. 2024 Mar 27;15(4):449-456. doi: 10.1021/acsmedchemlett.3c00538. eCollection 2024 Apr 11.
Chemotherapy has been ineffective in cancer treatment, and efficient delivery of chemotherapeutic agents remains a challenge. In this study, we developed a doxorubicin-loaded shilajit-based nanocarrier (SHN-Dox) using a nanoprecipitation method to enhance Dox uptake into breast cancer cells (MCF-7 and ZR-75-1). After confirmation of the physicochemical properties of the nanocarriers, the cytotoxic and pro-apoptotic effects of SHN-Dox and the production of reactive oxygen species (ROS) were evaluated on breast cancer cells. SHN-Dox showed a spherical shape with a size of 244 nm and a sustainable release profile of Dox. It exhibited high cytotoxicity against MCF-7 and ZR-75-1 cells, effectively inducing DNA fragmentation in these cells. After 24 h of treatment, SHN-Dox increased the apoptosis rate in MCF-7 cells and raised ROS levels. Therefore, SHN-Dox is a promising carrier that might reduce the side effects of Dox on healthy cells and provide a new strategy for clinical cancer treatment.
化疗在癌症治疗中效果不佳，化疗药物的有效递送仍然是一个挑战。在本研究中，我们采用纳米沉淀法开发了一种载有阿霉素的希拉季特基纳米载体（SHN-Dox），以增强阿霉素对乳腺癌细胞（MCF-7和ZR-75-1）的摄取。在确认纳米载体的物理化学性质后，评估了SHN-Dox对乳腺癌细胞的细胞毒性、促凋亡作用以及活性氧（ROS）的产生。SHN-Dox呈球形，尺寸为244 nm，具有阿霉素的持续释放特性。它对MCF-7和ZR-75-1细胞表现出高细胞毒性，有效诱导这些细胞中的DNA片段化。处理24小时后，SHN-Dox增加了MCF-7细胞的凋亡率并提高了ROS水平。因此，SHN-Dox是一种有前景的载体，可能会降低阿霉素对健康细胞的副作用，并为临床癌症治疗提供新策略。
Zotero 插件